|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions |
ISO |
[mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of COL10A1 mRNA; [mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of COL10A1 protein |
CTD |
PMID:27050768 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
[mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of COL2A1 mRNA; [mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of COL2A1 protein |
CTD |
PMID:27050768 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
mofezolac inhibits the reaction [[PTGS2 protein results in increased chemical synthesis of Prostaglandins] which results in increased expression of FOS mRNA] |
CTD |
PMID:9450688 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
mofezolac inhibits the reaction [IL1A protein results in increased abundance of Dinoprostone] |
CTD |
PMID:15167967 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
mofezolac inhibits the reaction [IL1B protein results in increased expression of IL1B mRNA] |
CTD |
PMID:9491209 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression increases secretion |
ISO |
mofezolac results in increased expression of IL1RN mRNA mofezolac results in increased secretion of IL1RN protein |
CTD |
PMID:9491209 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions decreases expression decreases activity |
ISO EXP |
[mofezolac results in decreased activity of PTGS1 protein] which results in decreased abundance of Dinoprostone; [mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of COL10A1 mRNA; [mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of COL10A1 protein; [mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of COL2A1 mRNA; [mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of COL2A1 protein; [mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of SOX9 mRNA; [mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of SOX9 protein mofezolac results in decreased expression of PTGS1 |
CTD |
PMID:21510291 PMID:27050768 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases activity multiple interactions |
EXP |
mofezolac results in decreased activity of PTGS2 protein mofezolac inhibits the reaction [[PTGS2 protein results in increased chemical synthesis of Prostaglandins] which results in increased expression of FOS mRNA] |
CTD |
PMID:9450688 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
ISO |
[mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of SOX9 mRNA; [mofezolac results in decreased activity of PTGS1 protein] which results in decreased expression of SOX9 protein |
CTD |
PMID:27050768 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|